Barclays’s Covetrus, Inc. Common Stock CVET Stock Holding History

Barclays’s Portfolio CVET Stock Details CVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-40,000	Closed	-$799K	–	5809
2021 Q4	$799K	Buy	+40,000	New	+$753K	﹤0.01%	2964
2020 Q1	–	Sell	-156,400	Closed	-$2.06M	–	6611
2019 Q4	$2.06M	Buy	+156,400	New	+$1.89M	﹤0.01%	2968
2019 Q3	–	Sell	-40	Closed	-$1K	–	7299
2019 Q2	$1K	Hold	40	–	–	﹤0.01%	6872
2019 Q1	$1K	Buy	+40	New	+$1.42K	﹤0.01%	6947

Other funds holding CVET

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's CVET Position: Q4 2022 in Review

Barclays sold out of Covetrus, Inc. Common Stock (CVET) in Q4 2022, closing a stake of 214,220 shares — an estimated $4.47M sold.

Barclays first reported a position in CVET in Q1 2019 and held it in 15 quarters. The position peaked at $4.57M in Q4 2020. 5 funds tracked by Wall St. Rank hold CVET as of Q4 2022.

Barclays reported no remaining Covetrus, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Barclays sold 214,220 Covetrus, Inc. Common Stock shares in Q4 2022, an estimated $4.47M.
Barclays first reported a position in Covetrus, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
Barclays's Covetrus, Inc. Common Stock position peaked at $4.57M in Q4 2020.
5 funds tracked by Wall St. Rank held Covetrus, Inc. Common Stock as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.